Morgens Waterfall Vintiadis & Co. Inc. bought a new stake in Crispr Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 30,000 shares of the company’s stock, valued at approximately $704,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CRSP. Farallon Capital Management LLC acquired a new stake in Crispr Therapeutics during the 4th quarter worth about $20,160,000. BlackRock Inc. grew its position in Crispr Therapeutics by 16,623.9% during the 4th quarter. BlackRock Inc. now owns 552,558 shares of the company’s stock worth $12,974,000 after purchasing an additional 549,254 shares during the period. Opaleye Management Inc. acquired a new stake in Crispr Therapeutics during the 4th quarter worth about $6,597,000. Capital Advisors Inc. OK acquired a new stake in Crispr Therapeutics during the 4th quarter worth about $3,515,000. Finally, Allianz Asset Management GmbH acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $2,384,000. 27.29% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Crispr Therapeutics AG (CRSP) opened at $56.72 on Monday. Crispr Therapeutics AG has a 12 month low of $13.50 and a 12 month high of $61.24.
In other news, major shareholder Aktiengesellschaft Bayer bought 527,472 shares of the stock in a transaction dated Friday, January 5th. The shares were acquired at an average cost of $22.75 per share, with a total value of $11,999,988.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kurt Von Emster sold 37,754 shares of the stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $26.76, for a total transaction of $1,010,297.04. The disclosure for this sale can be found here. Over the last three months, insiders have sold 298,850 shares of company stock worth $7,545,365. Corporate insiders own 39.98% of the company’s stock.
Several equities research analysts have weighed in on the company. SunTrust Banks reaffirmed a “buy” rating and set a $65.00 price target on shares of Crispr Therapeutics in a research report on Friday. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $53.70 price target (down from $67.00) on shares of Crispr Therapeutics in a research report on Friday. Barclays increased their price target on Crispr Therapeutics from $29.00 to $59.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 7th. Citigroup increased their price target on Crispr Therapeutics from $20.00 to $51.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 28th. Finally, ValuEngine raised Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Crispr Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $53.53.
ILLEGAL ACTIVITY WARNING: “Morgens Waterfall Vintiadis & Co. Inc. Invests $704,000 in Crispr Therapeutics AG (CRSP)” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://ledgergazette.com/2018/03/12/morgens-waterfall-vintiadis-co-inc-invests-704000-in-crispr-therapeutics-ag-crsp.html.
Crispr Therapeutics Profile
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Crispr Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.